Home

Awesome

Cancer Predisposition Sequencing Reporter <a href="https://sigven.github.io/cpsr/"><img src="man/figures/logo.png" align="right" height="118" width="100"/></a>

The Cancer Predisposition Sequencing Reporter (CPSR) is a computational workflow that interprets DNA sequence variants identified from next-generation sequencing in the context of cancer predisposition.

CPSR accepts a query file with germline variant calls (SNVs/InDels) from a single sample (i.e. cancer patient), encoded in the VCF format . Through comprehensive gene and variant annotation procedures, CPSR offers the following main functionalities to the user:

  1. Flexible selection of cancer predisposition genes subject to analysis and reporting - through the use of virtual gene panels
  2. Variant classification (Pathogenic to Benign) through a dedicated implementation of ACMG/AMP guidelines
  3. Detection of germline biomarkers - for prognosis, diagnosis, or drug sensitivity/resistance in cancer
  4. Reporting of secondary/incidental findings (ACMG recommendations)
  5. Interactive HTML output report with detailed variant information, gene annotations, and external links to relevant databases

The CPSR workflow is integrated with the framework that underlies the Personal Cancer Genome Reporter - PCGR. While PCGR is intended for reporting and analysis of somatic variants detected in a tumor, CPSR is intended for reporting and ranking of germline variants in protein-coding genes that are implicated in cancer predisposition and inherited cancer syndromes.

Snapshots of sections in the quarto-based cancer predisposition genome report (artificial sample, with more findings than usual) are shown below:

CPSR views

News

Example report

DOI

Getting started

Citation

If you use CPSR, please cite the following publication:

Sigve Nakken, Vladislav Saveliev, Oliver Hofmann, Pål Møller, Ola Myklebost, and Eivind Hovig. Cancer Predisposition Sequencing Reporter (CPSR): a flexible variant report engine for high-throughput germline screening in cancer (2021). Int J Cancer. [doi:10.1002/ijc.33749](https://doi.org/10.1002/ijc.33749)

Contact

sigven@ifi.uio.no